Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,099.75
(
-0.53%
)
US TECH 100
26,046.60
(
-0.60%
)
Dow Jones
49,230.21
(
-0.52%
)
Brent Oil
100.25
(
3.64%
)
Bitcoin
77,930.44
(
-0.39%
)
News Focus
News Focus
Post# of 822579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

HyGro

Send PM Follow Ignore
Followers 24
Posts 4175
Boards Moderated 0
Alias Born 12/18/2019

HyGro

Re: SkyLimit2022 post# 514238

Thursday, 09/15/2022 6:30:25 PM

Thursday, September 15, 2022 6:30:25 PM

Post# of 822579
And Dr. Liau reconfirmed PFS primary endpoint 14 years into the trial. Also selected PFS as the lead efficacy endpoint for her NCI SPORE Combination Keytruda immunotherapy trial too. But NWBO failed to meet the PFS primary endpoint and tossed it out.
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News